Update on HER-2 as a target for cancer therapy: alternative strategies for targeting the epidermal growth factor system in cancer.
The epidermal growth factor (EGF) family of ligands and receptors interact to influence cell division, differentiation and motility. Much evidence supports their importance in causing and sustaining cell transformation in model systems and in human cancer. The exact mechanism by which this is achieved varies in different tumour types and from case to case. The EGF system is a target for new types of targeted chemotherapy. The choice of strategy will depend on the mechanism involved, however, and several approaches are under development or evaluation in clinical trials. Each will have a different spectrum of side effects and the potential for development of drug resistance.
Gullick
W J
WJ
Department of Biosciences, University of Kent at Canterbury, Canterbury, Kent, UK. W.J.Gullick@ukc.ac.uk
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D066246:ErbB Receptors; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans
D000970:Antineoplastic Agents; D066246:ErbB Receptors